Home » Biotechnology » Japan Stem Cell Contract Manufacturing Market

Japan Stem Cell Contract Manufacturing Market By Scale of Operation (Commercial, Clinical, Preclinical); By Size of Contract Manufacturer (Large/Very Large, Mid-sized, Small-sized); By Source of Stem Cells (Allogenic, Autologous); By Type of Stem Cells (Adult Stem Cells (ASCs), Human Embryonic Stem Cells (HESCs), Induced Pluripotent Stem Cells (iPSCs)); By End-user (Biopharmaceutical Companies, Research Institutes, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
Japan Stem Cell Contract Manufacturing MarketSize 2024	USD 125.68 million
Japan Stem Cell Contract Manufacturing Market, CAGR	13%
Japan Stem Cell Contract Manufacturing Market Size 2032	USD 334.13 million

Market Overview:

The Japan Stem Cell Contract Manufacturing Market Is projected to grow from USD 125.68 million in 2024 to an estimated USD 334.13 million by 2032, with a compound annual growth rate (CAGR) of 13% from 2024 to 2032.

The growth of the Japan stem cell contract manufacturing market is driven by several critical factors. Increased prevalence of chronic and degenerative diseases such as diabetes, cardiovascular conditions, and neurodegenerative disorders has escalated the demand for stem cell therapies. Japan’s supportive regulatory environment, including the enactment of the Revised Pharmaceutical Affairs Law and the Act on the Safety of Regenerative Medicine, has streamlined the approval process for stem cell-based treatments, accelerating market growth. Moreover, advancements in stem cell technology, such as induced pluripotent stem cells (iPSCs) pioneered in Japan, have spurred innovation and global interest in outsourcing manufacturing to the region. The rising trend of collaborations between research institutions and biotechnology companies has further enhanced the market’s potential. Additionally, the demand for scalable and cost-effective manufacturing solutions has made contract manufacturing organizations (CMOs) an essential part of the stem cell supply chain.

Japan holds a significant position in the global stem cell contract manufacturing landscape, supported by its advanced infrastructure, strong research capabilities, and skilled workforce. The government’s active role in fostering regenerative medicine through funding and initiatives such as the Japan Agency for Medical Research and Development (AMED) has propelled the market forward. The presence of key industry players and research collaborations within Japan has created a highly competitive and innovative ecosystem. Tokyo and other metropolitan regions serve as major hubs for stem cell manufacturing and research, attracting both domestic and international stakeholders. Additionally, Japan’s strategic focus on exporting stem cell technologies and manufacturing services to other Asian and global markets further cements its leadership role in this sector.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Insights:

The Japan Stem Cell Contract Manufacturing Market is projected to grow significantly, from USD 125.68 million in 2024 to USD 334.13 million by 2032, at a CAGR of 13% during the forecast period.
Increasing prevalence of chronic and degenerative diseases, including diabetes and neurodegenerative disorders, is driving demand for stem cell therapies, positioning Japan as a leader in regenerative medicine.
Japan’s leadership in induced pluripotent stem cell (iPSC) technology, pioneered by its researchers, has created a surge in global interest for outsourcing manufacturing to the region.
Supportive regulations, including the Revised Pharmaceutical Affairs Law and Act on the Safety of Regenerative Medicine, streamline approvals, accelerating market growth.
Collaborations between biotechnology firms, research institutions, and CMOs are enhancing innovation, with Tokyo and metropolitan regions serving as primary hubs for manufacturing and research.
Challenges such as high manufacturing costs, stringent compliance requirements, and a limited skilled workforce impact scalability and market growth, particularly for smaller players.
Japan’s strategic focus on exporting stem cell technologies and its strong research infrastructure ensures a competitive edge in the global market for contract manufacturing.

Market Drivers:

Increasing Demand for Regenerative Medicine

The rising prevalence of chronic and degenerative diseases, such as diabetes, cardiovascular disorders, and neurodegenerative conditions, is a significant driver for the Japan stem cell contract manufacturing market. Stem cell-based therapies offer promising solutions for these conditions, fueling the demand for high-quality manufacturing capabilities. Japan’s aging population further accelerates this trend, as regenerative medicine emerges as a critical component in addressing age-related health challenges. For instance, the number of clinical trials for regenerative medicine in Japan has increased significantly, with over 90 trials approved as of 2014. The focus on developing effective therapies to restore or replace damaged tissues and organs has positioned stem cell manufacturing as a cornerstone of the country’s healthcare strategy.

Advancements in Stem Cell Technology

Japan’s leadership in induced pluripotent stem cell (iPSC) technology has been transformative for the market. The ability to reprogram adult cells into pluripotent stem cells has opened new avenues for drug discovery, personalized medicine, and regenerative applications. This breakthrough, pioneered by Japanese researchers, has created a global demand for contract manufacturing services specializing in iPSCs. For example, Kyoto University’s Center for iPS Cell Research and Application (CiRA) has generated iPS cells for 231 different diseases. Additionally, continuous innovation in bioprocessing technologies, such as single-use bioreactors and automated systems, is enabling manufacturers to enhance production scalability and efficiency, further driving market growth.

Supportive Regulatory Environment

Japan’s regulatory framework is a key enabler of the stem cell contract manufacturing market. The Revised Pharmaceutical Affairs Law and the Act on the Safety of Regenerative Medicine streamline the approval processes for stem cell-based therapies, encouraging both domestic and international companies to invest in the market. These regulations provide clear guidelines, ensuring safety and efficacy while reducing time-to-market for new therapies. The government’s proactive approach, including funding and policy initiatives, has fostered an ecosystem conducive to innovation and commercialization, strengthening the market’s growth potential. For instance, the Japanese government has committed 110 billion yen over 10 years to support regenerative medicine research.

Growing Collaborations and Outsourcing Trends

Collaborations between biotechnology firms, research institutions, and contract manufacturing organizations (CMOs) are becoming increasingly common in Japan. These partnerships enable the pooling of expertise and resources, accelerating the development and commercialization of stem cell therapies. For example, Osaka University has concluded a comprehensive collaboration agreement with Chugai Pharmaceutical, a longtime supporter of the university’s Immunology Frontier Research Center (IFReC), for support totaling 10 billion yen (approximately 67.6 million USD) over 10 years. Additionally, the global trend toward outsourcing stem cell manufacturing to regions with advanced infrastructure and regulatory support is driving international interest in Japan. The country’s robust research capabilities, skilled workforce, and reputation for high-quality production make it a preferred destination for outsourcing, further boosting the market.

Market Trends:

Growth in Induced Pluripotent Stem Cell (iPSC) Applications

Japan’s leadership in induced pluripotent stem cell (iPSC) technology is significantly shaping the market’s trajectory. This technology, pioneered in Japan, is witnessing rapid adoption for regenerative medicine, drug discovery, and disease modeling. Increasing investments in iPSC research and production have driven demand for contract manufacturing organizations (CMOs) capable of meeting the specific requirements of this cutting-edge field. For instance, over 200 academic institutes and companies globally are working on products using iPSC technology. The scalability and versatility of iPSCs are attracting global attention, making Japan a preferred hub for outsourcing such projects.

Rising Focus on Personalized Medicine

The growing trend toward personalized medicine is influencing the Japan stem cell contract manufacturing market. Stem cell therapies tailored to individual patients’ genetic profiles are gaining traction, particularly in oncology and rare disease treatment. This shift is driving the need for flexible and adaptable manufacturing capabilities that can accommodate small-batch production. For example, Tokyo Himawari Clinic uses advanced technologies to extract, cultivate, and return up to 300 million stem cells in a single session, compared to the industry standard of 50-150 million. Contract manufacturers are increasingly focusing on advanced technologies, such as single-use bioreactors and automation, to meet the requirements of this evolving trend while maintaining cost efficiency.

Expanding Role of Automation and Bioprocessing Technologies

The integration of automation and advanced bioprocessing technologies is revolutionizing stem cell manufacturing in Japan. Automated systems for cell culture, harvesting, and quality control are improving production efficiency and reducing the risk of human error. This technological shift is enabling manufacturers to scale production while maintaining high-quality standards. For instance, CellProthera’s StemXpand® automated manufacturing device and StemPack® single-use cell culture kits are used to produce clinical-grade autologous endothelial progenitor cell (EPC) therapies. The adoption of closed-system bioprocessing is particularly notable, allowing for a streamlined and contamination-free production environment, further enhancing the appeal of Japan’s contract manufacturing services.

Increasing Collaboration Between Industry and Academia

Collaborations between Japan’s leading academic institutions and biotechnology companies are fueling innovation and market expansion. Research institutes, such as Kyoto University, are working closely with CMOs to translate laboratory discoveries into scalable, commercially viable therapies. These partnerships are accelerating the development of novel stem cell applications and fostering a dynamic ecosystem that benefits both domestic and international stakeholders. For example, Kyoto University’s “KyotoU Model” for industry-academia collaboration aims to establish new large-scale businesses through practical cooperation. Additionally, the Japanese government’s active support through funding and policy initiatives is strengthening these collaborative efforts, positioning Japan as a global leader in stem cell contract manufacturing.

Market Challenges Analysis:

High Operational and Manufacturing Costs

One of the significant restraints in the Japan Stem Cell Contract Manufacturing Market is the high operational and manufacturing costs associated with stem cell therapies. The development and scaling of stem cell production require advanced facilities, skilled personnel, and stringent quality control processes, which substantially increase expenses. These high costs can deter smaller companies and research institutions from outsourcing their manufacturing needs, limiting market growth.

Stringent Regulatory Compliance

Although Japan’s regulatory environment is supportive, the stringent requirements for quality assurance and compliance with safety standards pose challenges for manufacturers. Adhering to regulations such as the Act on the Safety of Regenerative Medicine demands substantial investments in infrastructure, documentation, and quality management systems. Non-compliance risks can result in delays or rejection of products, affecting the timelines and profitability of manufacturing operations.

Limited Skilled Workforce

The market also faces challenges related to the availability of a skilled workforce specializing in stem cell production and advanced bioprocessing technologies. Stem cell manufacturing is a complex and highly specialized field that requires expertise in handling sensitive biological materials and operating sophisticated equipment. A shortage of skilled professionals can hinder the scalability and efficiency of production processes.

Market Competition and Scalability Issues

Intensifying competition from global contract manufacturers and the growing need for scalability create additional challenges. Smaller and mid-sized contract manufacturing organizations (CMOs) often struggle to compete with larger players that can leverage economies of scale and advanced technological capabilities. This imbalance can limit opportunities for smaller players to establish a foothold in the market.

Market Opportunities:

The Japan Stem Cell Contract Manufacturing Market offers significant opportunities driven by the increasing global demand for advanced stem cell therapies and the country’s leadership in induced pluripotent stem cell (iPSC) technology. Japan’s supportive regulatory framework, such as the Act on the Safety of Regenerative Medicine, facilitates faster approval and commercialization of stem cell-based treatments. This positions the nation as a preferred destination for contract manufacturing, especially for companies seeking high-quality, scalable, and compliant production solutions. With the growing prevalence of chronic and degenerative diseases such as diabetes and neurodegenerative disorders, the demand for stem cell therapies is expected to rise sharply, creating a robust market opportunity for both domestic and international manufacturers.

Moreover, advancements in bioprocessing and automation technologies present further opportunities for contract manufacturing organizations (CMOs) to enhance efficiency and scalability. The increasing collaboration between Japan’s leading research institutions and biotechnology firms fosters innovation, enabling the development of novel stem cell products and therapies. Additionally, the rise in personalized medicine and cell-based immunotherapies expands the scope for contract manufacturing in niche markets. Japan’s strategic focus on exporting its stem cell technologies and services to global markets amplifies growth prospects, making it a key hub in the global stem cell ecosystem. These dynamics underline Japan’s unique position to capitalize on emerging trends in regenerative medicine, offering significant opportunities for stakeholders across the value chain.

Market Segmentation Analysis:

The Japan Stem Cell Contract Manufacturing Market is segmented based on the scale of operation, size of contract manufacturer, source of stem cells, type of stem cells, and end-user, providing a comprehensive understanding of the market dynamics.

By Scale of Operation, the market is categorized into commercial, clinical, and preclinical segments. The commercial segment dominates due to the increasing demand for large-scale manufacturing of stem cell therapies, while the clinical segment is growing rapidly, driven by the high volume of clinical trials in Japan.

By Size of Contract Manufacturer, large/very large CMOs hold the largest share, leveraging advanced infrastructure and economies of scale. Mid-sized and small-sized CMOs are emerging, focusing on niche services and custom solutions.

By Source of Stem Cells, the market is divided into allogenic and autologous. Allogenic stem cells lead the segment, owing to their broader application potential, while autologous stem cells are gaining traction for personalized therapies.

By Type of Stem Cells, induced pluripotent stem cells (iPSCs) dominate the market, as Japan is a global leader in this technology. Adult stem cells (ASCs) and human embryonic stem cells (HESCs) also contribute significantly, with ASCs being widely used due to their established safety and efficacy.

By End-user, biopharmaceutical companies account for the largest share, driven by their need for scalable manufacturing. Research institutes also hold a substantial share, focusing on R&D, while the “others” segment includes hospitals and specialized clinics utilizing stem cell therapies.

Segmentation:

By Scale of Operation

Commercial
Clinical
Preclinical

By Size of Contract Manufacturer

Large/Very Large
Mid-sized
Small-sized

By Source of Stem Cells

Allogenic
Autologous

By Type of Stem Cells

Adult Stem Cells (ASCs)
Human Embryonic Stem Cells (HESCs)
Induced Pluripotent Stem Cells (iPSCs)

By End-user

Biopharmaceutical companies
Research Institutes
Others

Regional Analysis:

The Japan Stem Cell Contract Manufacturing Market is primarily concentrated within the country’s major metropolitan regions, where advanced infrastructure and robust research capabilities drive its growth. Tokyo, Osaka, and Kyoto are key hubs, contributing significantly to the market’s expansion due to their established biotechnology clusters, research institutions, and manufacturing facilities. These regions collectively account for over 65% of the market share, underscoring their dominance in the sector.

Tokyo, with its extensive network of universities, research centers, and biotechnology companies, holds the largest share of the market at approximately 35%. The city serves as a central hub for innovation and commercialization, driven by strong governmental support and collaborations between academia and industry. Tokyo’s strategic location and global connectivity make it an attractive base for international companies seeking to enter the Japanese market.

Osaka and the Kansai region contribute around 20% of the market, benefiting from their focus on regenerative medicine and the presence of key players in the pharmaceutical and biotechnology sectors. The region’s strong emphasis on innovation and manufacturing efficiency makes it a vital contributor to Japan’s stem cell manufacturing ecosystem.

Kyoto, accounting for approximately 10% of the market share, plays a pivotal role due to its historical leadership in stem cell research, particularly in induced pluripotent stem cell (iPSC) technology. Kyoto University and its associated research institutes have made groundbreaking advancements in stem cell science, attracting both domestic and international stakeholders.

Other regions, including Fukuoka and Hokkaido, collectively account for the remaining 35% of the market. These areas are gaining traction as emerging hubs, supported by local government initiatives and increasing investments in life sciences and biotechnology.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis:

WuXi AppTec
Boehringer Ingelheim
Catalent Inc.
Cytiva
AbbVie Inc.
AGC Biologics
FUJIFILM Diosynth Biotechnologies
Samsung Biologics
Thermo Fisher Scientific Inc.
Cytovance Biologics

Competitive Analysis:

The Japan Stem Cell Contract Manufacturing Market is highly competitive, driven by a blend of established global players and dynamic domestic companies. Leading firms leverage Japan’s expertise in induced pluripotent stem cell (iPSC) technology, advanced manufacturing infrastructure, and supportive regulatory environment to maintain a competitive edge. International companies often collaborate with local organizations to gain market access and capitalize on Japan’s robust ecosystem for stem cell research and production. The market’s competitiveness is further characterized by significant investments in R&D, automation, and bioprocessing innovations, enabling scalable and cost-effective manufacturing. For instance, companies have invested in state-of-the-art bioreactors and automated cell culture systems to enhance production efficiency and consistency. Firms compete on factors such as production quality, regulatory compliance, and the ability to meet customized client needs. Additionally, partnerships between biotechnology companies, academic institutions, and contract manufacturing organizations (CMOs) enhance market dynamics. As demand for stem cell-based therapies grows, players with advanced technological capabilities and strong industry networks are poised to lead this evolving and highly specialized market.

Recent Developments:

Cytiva has partnered with Cellular Origins to combine their technology platforms for automated, robotic manufacturing of cell and gene therapies. This collaboration, announced on January 16, 2025, aims to scale up CGT manufacturing to industrial levels, integrating Cytiva’s Sefia platform with Cellular Origins’ Constellation robotic platform.
On January 4, 2024, AbbVie and Umoja Biopharma announced two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology. This partnership leverages Umoja’s VivoVec™ gene delivery platform and AbbVie’s oncology expertise to potentially expand the patient populations and indications benefiting from CAR-T therapies
FUJIFILM Diosynth Biotechnologies announced an investment of $1.2 billion to expand its large-scale cell culture facility in Holly Springs, North Carolina, on April 12, 2024. This expansion will add 8 x 20,000 liters of bioreactor capacity, supporting the company’s Partners for Life strategy to enhance biopharma customers’ end-to-end need.
Samsung Biologics secured a landmark $1.24 billion contract with an Asia-based pharmaceutical company on October 22, 2024. This deal, the largest contract signed by a single client, will see production at Samsung Biologics’ biomanufacturing facilities, further expanding its capacity and client base in key regions like Japan.

Market Concentration & Characteristics:

The Japan Stem Cell Contract Manufacturing Market is moderately concentrated, with a mix of established players and emerging firms contributing to its competitive landscape. Leading companies leverage Japan’s advanced infrastructure, regulatory support, and expertise in induced pluripotent stem cell (iPSC) technology to maintain a competitive edge. The market is characterized by high innovation intensity, with significant investments in research and development driving advancements in stem cell applications and scalable production processes. Collaborations between biotechnology firms, academic institutions, and contract manufacturing organizations (CMOs) are a defining characteristic, fostering innovation and enhancing manufacturing capabilities. Quality compliance and regulatory alignment are critical, as stringent standards ensure safety and efficacy in stem cell-based therapies. Additionally, the market benefits from Japan’s skilled workforce and advanced bioprocessing technologies, which enable precision and efficiency in production. This combination of innovation, quality, and collaboration underscores the market’s unique characteristics and potential for sustained growth.

Report Coverage:

The research report offers an in-depth analysis based on By Scale of Operation, By Size of Contract Manufacturer, By Source of Stem Cells, By Type of Stem Cells and By End-user It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook:

The market is expected to achieve significant growth, driven by increased adoption of stem cell therapies for chronic and degenerative diseases.
Continued advancements in induced pluripotent stem cell (iPSC) technology will strengthen Japan’s global leadership in stem cell innovation.
Regulatory frameworks will remain a critical enabler, streamlining approval processes for novel stem cell-based treatments.
Expanding collaborations between research institutions and biotechnology firms will foster innovation and market expansion.
Growing international outsourcing of stem cell manufacturing to Japan will enhance its position as a global hub.
Increasing demand for scalable and cost-effective manufacturing will drive investments in contract manufacturing organizations (CMOs).
Government initiatives and funding for regenerative medicine will further support market growth and research advancements.
Emerging applications in personalized medicine and tissue engineering will create new opportunities for market players.
Enhanced automation and bioprocessing technologies will improve production efficiency and scalability.
Strategic focus on exporting stem cell technologies will boost Japan’s global market footprint and revenue streams.

CHAPTER NO. 1 : INTRODUCTION 19

1.1. Report Description 19

Purpose of the Report 19

USP & Key Offerings 19

1.2. Key Benefits for Stakeholders 19

1.3. Target Audience 20

1.4. Report Scope 20

CHAPTER NO. 2 : EXECUTIVE SUMMARY 21

2.1. Japan Stem Cell Contract Manufacturing Market Snapshot 21

2.2. Japan Stem Cell Contract Manufacturing Market, 2018 – 2032 (USD Million) 22

CHAPTER NO. 3 : JAPAN STEM CELL CONTRACT MANUFACTURING MARKET – INDUSTRY ANALYSIS 23

3.1. Introduction 23

3.2. Market Drivers 24

3.3. Supportive Regulatory Framework 24

3.4. Demand for Specialized Manufacturing Expertise 25

3.5. Market Restraints 26

3.6. Regulatory Complexity 26

3.7. Market Opportunities 27

3.8. Market Opportunity Analysis 27

3.9. Porter’s Five Forces Analysis 28

CHAPTER NO. 4 : ANALYSIS COMPETITIVE LANDSCAPE 29

4.1. Company Market Share Analysis – 2023 29

4.1.1. Japan Stem Cell Contract Manufacturing Market: Company Market Share, by Volume, 2023 29

4.1.2. Japan Stem Cell Contract Manufacturing Market: Company Market Share, by Revenue, 2023 30

4.1.3. Japan Stem Cell Contract Manufacturing Market: Top 6 Company Market Share, by Revenue, 2023 30

4.1.4. Japan Stem Cell Contract Manufacturing Market: Top 3 Company Market Share, by Revenue, 2023 31

4.2. Japan Stem Cell Contract Manufacturing Market Company Revenue Market Share, 2023 32

4.3. Company Assessment Metrics, 2023 33

4.3.1. Stars 33

4.3.2. Emerging Leaders 33

4.3.3. Pervasive Players 33

4.3.4. Participants 33

4.4. Start-ups /SMEs Assessment Metrics, 2023 33

4.4.1. Progressive Companies 33

4.4.2. Responsive Companies 33

4.4.3. Dynamic Companies 33

4.4.4. Starting Blocks 33

4.5. Strategic Developments 34

4.5.1. Acquisitions & Mergers 34

New Product Launch 34

Regional Expansion 34

4.6. Key Players Product Matrix 35

CHAPTER NO. 5 : PESTEL & ADJACENT MARKET ANALYSIS 36

5.1. PESTEL 36

5.1.1. Political Factors 36

5.1.2. Economic Factors 36

5.1.3. Social Factors 36

5.1.4. Technological Factors 36

5.1.5. Environmental Factors 36

5.1.6. Legal Factors 36

5.2. Adjacent Market Analysis 36

CHAPTER NO. 6 : JAPAN STEM CELL CONTRACT MANUFACTURING MARKET – BY SCALE OF OPERATION SEGMENT ANALYSIS 37

6.1. Japan Stem Cell Contract Manufacturing Market Overview, by Scale of Operation Segment 37

6.1.1. Japan Stem Cell Contract Manufacturing Market Revenue Share, By Scale of Operation, 2023 & 2032 38

6.1.2. Japan Stem Cell Contract Manufacturing Market Attractiveness Analysis, By Scale of Operation 39

6.1.3. Incremental Revenue Growth Opportunity, by Scale of Operation, 2024 – 2032 39

6.1.4. Japan Stem Cell Contract Manufacturing Market Revenue, By Scale of Operation, 2018, 2023, 2027 & 2032 40

6.2. Commercial 41

6.3. Clinical 42

6.4. Preclinical 43

CHAPTER NO. 7 : JAPAN STEM CELL CONTRACT MANUFACTURING MARKET – BY SIZE OF CONTRACT MANUFACTURER SEGMENT ANALYSIS 44

7.1. Japan Stem Cell Contract Manufacturing Market Overview, by Size of Contract Manufacturer Segment 44

7.1.1. Japan Stem Cell Contract Manufacturing Market Revenue Share, By Size of Contract Manufacturer, 2023 & 2032 45

7.1.2. Japan Stem Cell Contract Manufacturing Market Attractiveness Analysis, By Size of Contract Manufacturer 46

7.1.3. Incremental Revenue Growth Opportunity, by Size of Contract Manufacturer, 2024 – 2032 46

7.1.4. Japan Stem Cell Contract Manufacturing Market Revenue, By Size of Contract Manufacturer, 2018, 2023, 2027 & 2032 47

7.2. Large/Very Large 48

7.3. Mid-sized 49

7.4. Small-sized 50

CHAPTER NO. 8 : JAPAN STEM CELL CONTRACT MANUFACTURING MARKET – BY END-USER SEGMENT ANALYSIS 51

8.1. Japan Stem Cell Contract Manufacturing Market Overview, by End-user Segment 51

8.1.1. Japan Stem Cell Contract Manufacturing Market Revenue Share, By End-user, 2023 & 2032 52

8.1.2. Japan Stem Cell Contract Manufacturing Market Attractiveness Analysis, By End-user 53

8.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 53

8.1.4. Japan Stem Cell Contract Manufacturing Market Revenue, By End-user, 2018, 2023, 2027 & 2032 54

8.2. Biopharmaceutical companies 55

8.3. Research Institutes 56

8.4. Others 57

CHAPTER NO. 9 : JAPAN STEM CELL CONTRACT MANUFACTURING MARKET – BY SOURCE OF STEM CELLS SEGMENT ANALYSIS 58

9.1. Japan Stem Cell Contract Manufacturing Market Overview, by Source of Stem Cells Segment 58

9.1.1. Japan Stem Cell Contract Manufacturing Market Revenue Share, By Source of Stem Cells, 2023 & 2032 59

9.1.2. Japan Stem Cell Contract Manufacturing Market Attractiveness Analysis, By Source of Stem Cells 60

9.1.3. Incremental Revenue Growth Opportunity, by Source of Stem Cells, 2024 – 2032 60

9.1.4. Japan Stem Cell Contract Manufacturing Market Revenue, By Source of Stem Cells, 2018, 2023, 2027 & 2032 61

9.2. Allogenic 62

9.3. Autologous 63

CHAPTER NO. 10 : JAPAN STEM CELL CONTRACT MANUFACTURING MARKET – BY TYPE OF STEM CELLS SEGMENT ANALYSIS 64

10.1. Japan Stem Cell Contract Manufacturing Market Overview, by Type of Stem Cells Segment 64

10.1.1. Japan Stem Cell Contract Manufacturing Market Revenue Share, By Type of Stem Cells, 2023 & 2032 65

10.1.2. Japan Stem Cell Contract Manufacturing Market Attractiveness Analysis, By Type of Stem Cells 66

10.1.3. Incremental Revenue Growth Opportunity, by Type of Stem Cells, 2024 – 2032 66

10.1.4. Japan Stem Cell Contract Manufacturing Market Revenue, By Type of Stem Cells, 2018, 2023, 2027 & 2032 67

10.2. Adult Stem Cells (ASCs) 68

10.3. Human Embryonic Stem Cells (HESCs) 69

10.4. Induced Pluripotent Stem Cells (iPSCs) 70

CHAPTER NO. 11 : STEM CELL CONTRACT MANUFACTURING MARKET – ANALYSIS 71

11.1.1. Japan Stem Cell Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 71

11.1.2. Japan Stem Cell Contract Manufacturing Market Revenue, By Size of Contract Manufacturer, 2018 – 2023 (USD Million) 72

11.1.3. Japan Stem Cell Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 73

11.1.4. Japan Stem Cell Contract Manufacturing Market Revenue, By Source of Stem Cells, 2018 – 2023 (USD Million) 74

11.1.5. Japan Stem Cell Contract Manufacturing Market Revenue, By Type of Stem Cells, 2018 – 2023 (USD Million) 75

CHAPTER NO. 12 : COMPANY PROFILES 76

12.1. Lonza Group 76

12.1.1. Company Overview 76

12.1.2. Product Portfolio 76

12.1.3. Swot Analysis 76

12.1.4. Business Strategy 77

12.1.5. Financial Overview 77

12.2. WuXi AppTec 78

12.3. Boehringer Ingelheim 78

12.4. Catalent Inc. 78

12.5. Cytiva 78

12.6. AbbVie Inc. 78

12.7. AGC Biologics 78

12.8. FUJIFILM Diosynth Biotechnologies 78

12.9. Samsung Biologics 78

12.10. Thermo Fisher Scientific Inc. 78

12.11. Cytovance Biologics 78

List of Figures

FIG NO. 1. Japan Stem Cell Contract Manufacturing Market Revenue, 2018 – 2032 (USD Million) 22

FIG NO. 2. Porter’s Five Forces Analysis for Japan Stem Cell Contract Manufacturing Market 28

FIG NO. 3. Company Share Analysis, 2023 29

FIG NO. 4. Company Share Analysis, 2023 30

FIG NO. 5. Company Share Analysis, 2023 30

FIG NO. 6. Company Share Analysis, 2023 31

FIG NO. 7. Japan Stem Cell Contract Manufacturing Market – Company Revenue Market Share, 2023 32

FIG NO. 8. Japan Stem Cell Contract Manufacturing Market Revenue Share, By Scale of Operation, 2023 & 2032 38

FIG NO. 9. Market Attractiveness Analysis, By Scale of Operation 39

FIG NO. 10. Incremental Revenue Growth Opportunity by Scale of Operation, 2024 – 2032 39

FIG NO. 11. Japan Stem Cell Contract Manufacturing Market Revenue, By Scale of Operation, 2018, 2023, 2027 & 2032 40

FIG NO. 12. Japan Stem Cell Contract Manufacturing Market for Commercial, Revenue (USD Million) 2018 – 2032 41

FIG NO. 13. Japan Stem Cell Contract Manufacturing Market for Clinical, Revenue (USD Million) 2018 – 2032 42

FIG NO. 14. Japan Stem Cell Contract Manufacturing Market for Preclinical, Revenue (USD Million) 2018 – 2032 43

FIG NO. 15. Japan Stem Cell Contract Manufacturing Market Revenue Share, By Size of Contract Manufacturer, 2023 & 2032 45

FIG NO. 16. Market Attractiveness Analysis, By Size of Contract Manufacturer 46

FIG NO. 17. Incremental Revenue Growth Opportunity by Size of Contract Manufacturer, 2024 – 2032 46

FIG NO. 18. Japan Stem Cell Contract Manufacturing Market Revenue, By Size of Contract Manufacturer, 2018, 2023, 2027 & 2032 47

FIG NO. 19. Japan Stem Cell Contract Manufacturing Market for Large/Very Large, Revenue (USD Million) 2018 – 2032 48

FIG NO. 20. Japan Stem Cell Contract Manufacturing Market for Mid-sized, Revenue (USD Million) 2018 – 2032 49

FIG NO. 21. Japan Stem Cell Contract Manufacturing Market for Small-sized, Revenue (USD Million) 2018 – 2032 50

FIG NO. 22. Japan Stem Cell Contract Manufacturing Market Revenue Share, By End-user, 2023 & 2032 52

FIG NO. 23. Market Attractiveness Analysis, By End-user 53

FIG NO. 24. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 53

FIG NO. 25. Japan Stem Cell Contract Manufacturing Market Revenue, By End-user, 2018, 2023, 2027 & 2032 54

FIG NO. 26. Japan Stem Cell Contract Manufacturing Market for Biopharmaceutical companies, Revenue (USD Million) 2018 – 2032 55

FIG NO. 27. Japan Stem Cell Contract Manufacturing Market for Research Institutes, Revenue (USD Million) 2018 – 2032 56

FIG NO. 28. Japan Stem Cell Contract Manufacturing Market for Others, Revenue (USD Million) 2018 – 2032 57

FIG NO. 29. Japan Stem Cell Contract Manufacturing Market Revenue Share, By Source of Stem Cells, 2023 & 2032 59

FIG NO. 30. Market Attractiveness Analysis, By Source of Stem Cells 60

FIG NO. 31. Incremental Revenue Growth Opportunity by Source of Stem Cells, 2024 – 2032 60

FIG NO. 32. Japan Stem Cell Contract Manufacturing Market Revenue, By Source of Stem Cells, 2018, 2023, 2027 & 2032 61

FIG NO. 33. Japan Stem Cell Contract Manufacturing Market for Allogenic, Revenue (USD Million) 2018 – 2032 62

FIG NO. 34. Japan Stem Cell Contract Manufacturing Market for Autologous, Revenue (USD Million) 2018 – 2032 63

FIG NO. 35. Japan Stem Cell Contract Manufacturing Market Revenue Share, By Type of Stem Cells, 2023 & 2032 65

FIG NO. 36. Market Attractiveness Analysis, By Type of Stem Cells 66

FIG NO. 37. Incremental Revenue Growth Opportunity by Type of Stem Cells, 2024 – 2032 66

FIG NO. 38. Japan Stem Cell Contract Manufacturing Market Revenue, By Type of Stem Cells, 2018, 2023, 2027 & 2032 67

FIG NO. 39. Japan Stem Cell Contract Manufacturing Market for Adult Stem Cells (ASCs), Revenue (USD Million) 2018 – 2032 68

FIG NO. 40. Japan Stem Cell Contract Manufacturing Market for Human Embryonic Stem Cells (HESCs), Revenue (USD Million) 2018 – 2032 69

FIG NO. 41. Japan Stem Cell Contract Manufacturing Market for Induced Pluripotent Stem Cells (iPSCs), Revenue (USD Million) 2018 – 2032 70

List of Tables

TABLE NO. 1. : Japan Stem Cell Contract Manufacturing Market: Snapshot 21

TABLE NO. 2. : Drivers for the Japan Stem Cell Contract Manufacturing Market: Impact Analysis 24

TABLE NO. 3. : Restraints for the Japan Stem Cell Contract Manufacturing Market: Impact Analysis 26

TABLE NO. 4. : Japan Stem Cell Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 71

TABLE NO. 5. : Japan Stem Cell Contract Manufacturing Market Revenue, By Scale of Operation, 2024 – 2032 (USD Million) 71

TABLE NO. 6. : Japan Stem Cell Contract Manufacturing Market Revenue, By Size of Contract Manufacturer, 2018 – 2023 (USD Million) 72

TABLE NO. 7. : Japan Stem Cell Contract Manufacturing Market Revenue, By Size of Contract Manufacturer, 2024 – 2032 (USD Million) 72

TABLE NO. 8. : Japan Stem Cell Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 73

TABLE NO. 9. : Japan Stem Cell Contract Manufacturing Market Revenue, By End-user, 2024 – 2032 (USD Million) 73

TABLE NO. 10. : Japan Stem Cell Contract Manufacturing Market Revenue, By Source of Stem Cells, 2018 – 2023 (USD Million) 74

TABLE NO. 11. : Japan Stem Cell Contract Manufacturing Market Revenue, By Source of Stem Cells, 2024 – 2032 (USD Million) 74

TABLE NO. 12. : Japan Stem Cell Contract Manufacturing Market Revenue, By Type of Stem Cells, 2018 – 2023 (USD Million) 75

TABLE NO. 13. : Japan Stem Cell Contract Manufacturing Market Revenue, By Type of Stem Cells, 2024 – 2032 (USD Million) 75

Frequently Asked Questions

What drives the growth of the Japan stem cell contract manufacturing market?

The market is driven by increased demand for stem cell therapies due to the rising prevalence of chronic diseases, a supportive regulatory environment, advancements in stem cell technologies like iPSCs, and collaborations between research institutions and biotech companies.

What are the main regional advantages of Japan in the stem cell market?

Japan’s advanced infrastructure, strong research capabilities, skilled workforce, and government support position it as a leader in the global stem cell contract manufacturing market.

Which cities are key hubs for stem cell manufacturing in Japan?

Tokyo and other metropolitan regions are major hubs, hosting leading industry players, research institutions, and manufacturing facilities.

What are the challenges faced by the Japan stem cell contract manufacturing market?

Challenges include high operational costs, stringent quality control requirements, and the need for skilled personnel to manage complex manufacturing processes.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$5699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –